Skip to main content
Resolution ctDx FIRST Assay

Resolution ctDx FIRST Assay

Agilent Resolution ctDx FIRST is a liquid biopsy NGS assay optimized for cancer genomic profiling. ctDx FIRST is an FDA approved companion diagnostic to KRAZATI™ (adagrasib) for the detection of KRAS G12C in non-small cell lung cancer (NSCLC) and provides tumor mutation profiling for single nucleotide variants (SNVs) and deletions in the EGFR gene.

Additionally, the professional services portion of the test report (CLIA-certified, not FDA approved) includes comprehensive genomic profiling on 109 genes across 4 types of alterations: SNVs, insertions and deletions (indels), copy number amplifications (CNAs), and fusions.

Related Products Promotions
For additional product information or to order this test, fill out this form here.

0 part selected.

Clear All